P 3298

Drug Profile

P 3298

Alternative Names: P-32-98; P32/98

Latest Information Update: 22 Feb 2008

Price : $50

At a glance

  • Originator Probiodrug
  • Class Antihyperglycaemics; Thiazolidines
  • Mechanism of Action CD26 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Type 2 diabetes mellitus

Most Recent Events

  • 04 Dec 2002 Probiodrug has granted a non-exclusive licence to Ferring and its sublicensee, Ortho-McNeil Pharmaceuticals, for the inhibitors if dipeptidyl peptidase IV for diabetes and obesity
  • 06 Apr 2001 Phase-II clinical trials for Type-2 diabetes mellitus in Germany (PO)
  • 20 Feb 2001 A study has been added to the adverse events section
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top